SCHEMBL1146473

SCHEMBL1146473

Cc1ccc(-c2cnc(O[C@H]3CC[N@@]4CCC[C@H]3C4)nc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.47
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRM2 P08172 2/20 0.34
CHRM1 P11229 2/20 0.34
NTMT1 Q9BV86 1/20 0.34
CHRM3 P20309 1/20 0.34
MAPT P10636 1/20 0.33
ALDH1A1 P00352 1/20 0.33
DGAT1 O75907 1/20 0.32
PRCP P42785 1/20 0.32
HTT P42858 2/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1146472 1.00 CHRNA7 (0.47) CHRNA7NPSR1CYP1A2CYP2D6CHRNB1
SCHEMBL1146173 0.87 CHRNA7 (0.46) CHRNA7CYP1A2CYP2D6CHRNB1CHRNB2
SCHEMBL1146170 0.87 CHRNA7 (0.46) CHRNA7CYP1A2CYP2D6CHRNB1CHRNB2
SCHEMBL999386 0.85 CHRNA7 (0.64) CHRNA7NPSR1CYP1A2CYP2D6CHRM2
SCHEMBL999385 0.85 CHRNA7 (0.64) CHRNA7NPSR1CYP1A2CYP2D6CHRM2
SCHEMBL1145822 0.83 CHRNA7 (0.38) CHRNA7HCRTR1HCRTR2
SCHEMBL1145826 0.83 CHRNA7 (0.38) CHRNA7HCRTR1HCRTR2
SCHEMBL1146358 0.82 HTR3A (0.36) CHRNA7CHRM2CHRM1CHRM3
SCHEMBL1146361 0.82 HTR3A (0.36) CHRNA7CHRM2CHRM1CHRM3
SCHEMBL1146345 0.80 CHRNA7 (0.75) CHRNA7CYP1A2CYP2D6CHRNB1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761533-B1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2011-04-20 EP claimed
US-9475811-B2 1-aza-bicyclo[3.3.1]nonanes NOVARTIS AG (CH) 2016-10-25 US disclosed
US-20150087650-A1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2015-03-26 US disclosed
US-8933090-B2 1-aza-bicyclo[3.3.1]nonanes NOVARTIS AG (CH) 2015-01-13 US disclosed
EP-1761533-B8 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2011-10-12 EP disclosed
EP-2336129-A1 1-aza-bicyclo[3.3.1]nonanes Novartis AG (CH) 2011-06-22 EP disclosed
EP-1761533-B1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2011-04-20 EP disclosed
US-20110034475-A1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG 2011-02-10 US disclosed
US-20070249657-A1 1-Aza-Bicyclo3.3.1Nonanes NOVARTIS AG (CH) 2007-10-25 US disclosed
EP-1761533-A1 1-AZA-BICYCLO[3.3.1]NONANES Novartis AG (CH) 2007-03-14 EP disclosed
WO-2005123732-A1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249657-A1 1-Aza-Bicyclo3.3.1Nonanes CBR3, CBR1, HCAR3 CHRNA7 119/4885NPSR1 495/4885CYP1A2 201/4885
US-20110034475-A1 1-AZA-BICYCLO[3.3.1]NONANES CBR3, CBR1, HRH4 CHRNA7 208/4885NPSR1 383/4885CYP1A2 105/4885
US-20150087650-A1 1-AZA-BICYCLO[3.3.1]NONANES CBR3, CBR1, ADCY3 CHRNA7 228/4885NPSR1 387/4885CYP1A2 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.